<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102718">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02155660</url>
  </required_header>
  <id_info>
    <org_study_id>D3251C00004</org_study_id>
    <nct_id>NCT02155660</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History</brief_title>
  <acronym>TERRANOVA</acronym>
  <official_title>A Randomised, Double-blind, Double Dummy, 56 Week Placebo-controlled, Multicentre, Parallel Group, Phase 3 Study Evaluating Efficacy/Safety of 3 Benralizumab Doses in Patients With Moderate to Very Severe COPD With Previous Exacerbations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica</authority>
    <authority>Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos</authority>
    <authority>Peru: Ministry of Health</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Bulgaria: Bulgarian Drug Agency</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Ukraine: Ministry of Health</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Denmark: Danish Medicines Agency (DKMA) Leademiddelstyrelsen Axel heides</authority>
    <authority>Norway: Norwegian Medicines Agency (NoMA)</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>Turkey: Ministry of Health</authority>
    <authority>Brazil: National Health Surveillance Agency</authority>
    <authority>Mexico: Federal Commission for Sanitary Risks Protection</authority>
    <authority>Israel: Ethics Commission</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in
      symptomatic patients with moderate to very severe COPD who are receiving standard of care
      therapies.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Evaluation of the effect of benralizumab on COPD exacerbations in subjects with moderate to very severe COPD</measure>
    <time_frame>Immediately following administration of study drug up to 56 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Annual COPD (Chronic Obstructive Pulmonary Disease) exacerbation rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of benralizumab on health status/health-related quality of life</measure>
    <time_frame>up to 56 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>St. George's Respiratory Questionnaire (SGRQ ), Chronic Obstructive Pulmonary Disease assessment tool (CAT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of benralizumab on pulmonary function</measure>
    <time_frame>up to 56 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pre-dose/pre-bronchodilator Forced expiratory volume in one second (FEV1) at the study center</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of benralizumab on respiratory symptoms</measure>
    <time_frame>up to 56 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Baseline/Transitional Dyspnea Index (BDI/TDI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of benralizumab on rescue medication use</measure>
    <time_frame>up to 56 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total rescue medication use (average puffs/day), recorded by patient using electronic diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of benralizumab on nocturnal awakenings</measure>
    <time_frame>up to 56 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of nights with awakening due to COPD, recorded by patient using electronic diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of benralizumab on the severity, frequency and duration of Exacerbations of Chronic Pulmonary Disease Tool (EXACT-PRO) - Patient-reported Outcome questionnaire defined events</measure>
    <time_frame>up to 56 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Exacerbations of Chronic Pulmonary Disease Tool (EXACT-PRO) - Patient-reported Outcome questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of benralizumab on healthcare resource utilization</measure>
    <time_frame>up to 56 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Annual rate of hospitalizations, combined hospitalizations and emergency department visits, unscheduled visits and healthcare encounters due to COPD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the benralizumab concentration in serum</measure>
    <time_frame>up to 60 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pharmacokinetics (PK) - steady-state serum pre-dose concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the safety and tolerability of benralizumab</measure>
    <time_frame>From baseline visit up to 56 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse Events/ Serious Adverse Events (AE/SAE) - Laboratory variables - 12 lead Electrocardiogram (ECG) - Physical Examination - Vital Signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the immunogenicity of benralizumab</measure>
    <time_frame>up to 60 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determination of Anti-drug antibodies (ADA)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluation of the effect of benralizumab on general health status</measure>
    <time_frame>up to 56 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>European Quality of Life-5 Dimensions (EQ-5D-5L) questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of the impact of benralizumab on blood eosinophil levels</measure>
    <time_frame>up to 60 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood eosinophils levels</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">4850</enrollment>
  <condition>Moderate to Very Severe Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Benralizumab Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benralizumab administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benralizumab Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benralizumab administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benralizumab Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benralizumab administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benralizumab Arm A</intervention_name>
    <description>Benralizumab subcutaneously on study week 0 until study week 48 inclusive</description>
    <arm_group_label>Benralizumab Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benralizumab Arm B</intervention_name>
    <description>Benralizumab subcutaneously on study week 0 until study week 48 inclusive</description>
    <arm_group_label>Benralizumab Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benralizumab Arm C</intervention_name>
    <description>Benralizumab subcutaneously on study week 0 until study week 48 inclusive</description>
    <arm_group_label>Benralizumab Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Benralizumab subcutaneously on study week 0 until study week 48 inclusive</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:.

          -  Informed consent.

          -  Subjects 40-85 y.o.

          -  Moderate to very severe COPD with Post Bronchodilator (BD) FEV1&gt;20% and ≤65%.

             -≥2 moderate or ≥1 severe COPD exacerbation(s) required treatment or hospitalization
             within 2-52 weeks prior to Visit1.

          -  Modified Medical Research Council (mMRC) score ≥1 at Visit 1.

          -  Treatment with double or triple therapy in the year prior to Visit 1, constant 2
             weeks prior to Visit 1.

          -  Tobacco history of ≥10 pack-years.

          -  Women of childbearing potential must use a highly effective form of birth control
             from Visit 1 until 16 weeks after their last dose, and negative serum pregnancy test
             result at Visit 1.

          -  Male subjects who are sexually active must be surgically sterile one year prior to
             Visit 1 or use an adequate method of contraception from the first Investigational
             Product (IP) dose until 16 weeks after their last dose.

          -  Compliance with maintenance therapy during run-in ≥70%.

        Exclusion criteria:

          -  Clinically important pulmonary disease other than COPD or another diagnosed pulmonary
             or systemic disease associated with elevated peripheral eosinophil counts.

          -  Any disorder or major physical impairment that is not stable by Investigator opinion
             and could affect: - subject safety−study findings or their interpretation or
             subject's ability to complete the entire study duration.

          -  Unstable ischemic heart disease, arrhythmia, cardiomyopathy, or other relevant
             cardiovascular disorder that in Investigator's judgment may put the patient at risk
             or negatively affect the study outcome.

          -  Treatment with systemic corticosteroids and/or antibiotics, and/or hospitalization
             for a COPD exacerbation within 2 weeks prior to Visit1.

          -  Acute upper or lower respiratory infection requiring antibiotics or antiviral
             medication within 2 weeks prior to Visit1.

          -  Pneumonia within 8 weeks prior to Visit1.

          -  Pregnant, breastfeeding, or lactating women.

          -  Risk factors for pneumonia

          -  History of anaphylaxis to any other biologic therapy.

          -  Long term oxygen therapy with signs and/or symptoms of cor pulmonale, right
             ventricular failure.

          -  Use of immunosuppressive medication within 28 days prior to randomisation.

          -  Receipt of any investigational non-biologic product within 30 days or 5 half-lives
             prior to Visit 1.

          -  Evidence of active tuberculosis (TB), either treated or untreated, or latent TB
             without an appropriate course of treatment.

          -  Lung volume reduction surgery within the 6 months prior to Visit 1. History of
             partial or total lung resection (single lobe or segmentectomy is acceptable).

          -  Asthma as a primary or main diagnosis according to the Global Initiative for Asthma
             (GINA) guidelines or other accepted guidelines.

          -  Previous treatment with benralizumab.

          -  Helminth parasitic infection diagnosed within 24 weeks prior to Visit 1.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bartolome R. Celli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital, Pulmonary Division, 75 Francis Street, PBB Clinics 3, Boston, MA 02115</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ClinicalTrialTransparency</last_name>
    <email>ClinicalTrialTransparency@astrazeneca.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>AstraZeneca Clinica Study Information</last_name>
    <phone>+ 800-236-9933</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woodstock</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buckley</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clabash</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shelby</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brussels (Laeken)</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brasília</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fortaleza</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Juiz de Fora</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santo André</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sorocaba</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vitória</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dupnitsa</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kozloduy</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pazardzhik</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pernik</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Petrich</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ruse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vratsa</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yambol</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durango</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cusco</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Mexico</country>
    <country>Peru</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>May 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obstructive Lung Diseases</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>Lung Disease</keyword>
  <keyword>Bronchial Diseases</keyword>
  <keyword>COPD Exacerbation</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
